Navigation Links
DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
Date:10/1/2007

MUNICH, Germany, October 1 /PRNewswire/ --

- New Product Under Development for the Treatment of High Blood Pressure

- Approval Requested in 28 European Countries

DAIICHI SANKYO EUROPE GmbH has applied in 28 European countries for approval of a new antihypertensive medication. It is a fixed combination (CS-8663) of two substances, the angiotensin receptor blocker (ARB) Olmesartan and the calcium antagonist Amlodipin.

When approved, the new combination for treatment of essential hypertension is designed for use in patients whose blood pressure cannot be adequately controlled through therapy with the respective monopreparation. In clinical trials the combination of Olmesartan / Amlodipin (CS-8663) has shown a significant lowering of blood pressure. In the new fixed combination, two complementary therapeutic approaches are combined: blocking of the angiotensin II receptor and blocking of the calcium channel. Olmesartan is already being marketed by DAIICHI SANKYO and is the angiotensin receptor blocker with the greatest sales growth in Europe(1). Amlodipin is one of the most frequently used calcium antagonists in many European countries.

"Hypertension is currently viewed as the number one cause of death. Most patients need two or even more medications to normalise their blood pressure. The new fixed combination has proved to be effective and well tolerated in a large number of patients. That also applies to patients who have very high blood pressure at the start of therapy," says Dr Petra Laeis, Head of Clinical Research at DAIICHI SANKYO EUROPE. "The combination of the two well-known agents Olmesartan and Amlodipin in one tablet gives doctors another effective treatment option for hypertension, which can lead to better results because patients are more likely to use it faithfully," continues Dr Laeis.

DAIICHI SANKYO is a worldwide, research-oriented pharmaceutical company, created through the merger of the two traditional Japan
'/>"/>

SOURCE DAIICHI SANKYO EUROPE GmbH
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
2. Development of a CRF1 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
3. A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors)
4. Merge launches diagnostic mammography workstation in Europe
5. Mirus granted European patent for gene therapy
6. Johnson Controls to expand in Europe
7. Innovation thrives in Europe
8. Info security group announces first Eastern European chapter
9. EMD Biosciences partners with European biotech company
10. Third Wave lands European distribution deal, reports high earnings
11. Third Wave seeks approval of Cystic Fibrosis test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 Flagship Biosciences LLC, ... services to the pharmaceutical and medical device industries, has ... The fast growing company has consolidated its histology and ... Boulder to Westminster, CO, just north of Denver. ... 7575 W. 103rd Ave., Suite 100, Westminster, CO 80021 ...
(Date:8/27/2014)... , Aug. 27, 2014 Research and ... "Global Enzyme for Pulp & Paper Industry Report 2014" ... Global Enzyme for Pulp & Paper Industry Report 2014 ... state of the global enzyme for pulp & paper ... of the industry including definitions, classifications, applications and industry ...
(Date:8/27/2014)... Aug. 27, 2014 Research and Markets ... Isotope Ratio Mass Spectrometer Industry Report 2014" report ... Isotope Ratio Mass Spectrometer Industry Report 2014 is a ... the global isotope ratio mass spectrometer industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... -- ARCH Venture Partners, one of the largest U.S. ... seed and early-stage advanced technology companies, today announced ... than $400 million in subscriptions. ARCH Venture Fund ... more than $150 million. "The enthusiasm ... of our approach to finding and funding new ...
Breaking Biology Technology:Flagship Biosciences Announces Relocation and Expansion 2Global Enzyme for Pulp & Paper Industry Report 2014 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... the Board ... Neill Named President, ISELIN, N.J., Jan. 3 Pharmos Corporation,(Nasdaq: ... effective immediately., Board Changes, Robert F. Johnston has been elected ... and Mony Ben Dor have retired from,the Board., The Pharmos Board ...
... Jan. 3 Cambrex,Corporation (NYSE: CBM ) ... President and Chief Executive Officer, will make a ... on January 8, 2008 at,9:00 a.m. PST at ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO ), A live ...
... Manufacture; Genzyme will Continue to Market and ... ... CAMBRIDGE, Mass., Jan. 3 ,BioMarin Pharmaceutical Inc. (Nasdaq and SWX: ... restructuring of their joint venture,regarding Aldurazyme(R) (laronidase). Under the revised ...
Cached Biology Technology:Pharmos Corporation Announces Board and Management Changes 2Pharmos Corporation Announces Board and Management Changes 3BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 2BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 3BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 4BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 5
(Date:8/27/2014)... North Carolina State University have found that century-old museum specimens ... common insect pest that can weaken and kill trees ... that scale insect populations increase on oak and maple trees ... pests may also increase with global warming," says Dr. Elsa ... of a paper on the work. , "More scale insects ...
(Date:8/26/2014)... University in St. Louis have developed algorithms to identify ... tearing or breaking. The technology, which needs to be ... may help pinpoint minor strains and tiny injuries in ... The research is available online Aug. 27 in the ... publishes research at the nexus of the physical and ...
(Date:8/26/2014)... colony of harmful bacteria, biofilms make the treatment ... a biofilm pose a significant health risk due ... and biofilm-protected bacteria account for some 80 percent ... 50 to 1,000 times more resistant to antibiotics ... may have stumbled onto a magic bullet," said ...
Breaking Biology News(10 mins):Museum specimens, modern cities show how an insect pest will respond to climate change 2New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3
... system, every protein made in the cell has a specific ... proteins to their appropriate target. Researchers at Boston University ... images of these channels as they open to allow proteins ... made. These findings are published as a Letter in ...
... apps, cameras, and mobile internet to navigate strange cities in ... in line, and upload their videos directly to social media ... high-tech savvy can save a well-loved device from dying when ... same basic ailment that plagues solar power plants and wind ...
... A drug currently on the market to treat leukemia reversed ... findings by medical researchers with the University of Alberta. ... team,s discovery in the peer-reviewed journal, PLOS ONE . ... can also play an important role in the development of ...
Cached Biology News:Researchers capture images of open channel that moves proteins across cell membranes 2Futuristic copper foam batteries get more bang for the buck 2Futuristic copper foam batteries get more bang for the buck 3UAlberta medical researchers discover potential new treatment for colitis 2UAlberta medical researchers discover potential new treatment for colitis 3
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
GOAT ANTI FRK...
UV LAMP 300 NM 8W T5, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: